我們已在上線!
進一步了解
PRVB
Provention Bio, Inc. Common Stock
PRVB
PRVB
已下市
PRVB已於2023年4月26日下市。
關於: Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.
員工: 174
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
我們尚未收到任何關於PRVB的最新新聞文章。
價格圖表採用Lightweight Charts™實作